Company news
Celularity Inc. news in 2021
Celularity Inc.'s news releases, calls and decks from 2021, newest first.
Celularity Receives Fast Track Designation from U.S. FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML
December 26, 2021
Celularity Announces FDA Clearance of Investigational New Drug Application (IND) for Natural Killer Cell Therapy CYNK-101 in First-line Advanced Her2/neu Positive Gastric and Gastroesophageal Junction Cancer
November 28, 2021
Celularity Reports Third Quarter 2021 Financial Results and Corporate Update
November 11, 2021
Celularity and Oncternal Therapeutics Enter into Research Collaboration to Evaluate Targeted Placental-Derived Cellular Therapies
September 19, 2021
Celularity Appoints Andrew L. Pecora, M.D., F.A.C.P., C.P.E., as President
September 14, 2021
Celularity Reports Second Quarter 2021 Financial Results
August 15, 2021
Decks in 2021
- Corporate Update (December 2021)
Corporate update · 16 slides · Dec 17, 2021
- Investor Presentation (October 2021)
Investor deck · 44 slides · October 2021
- Investor Presentation (October 2021)
Investor deck · 44 slides · October 2021
- Investor Presentation (July 2021)
Investor deck · 51 slides · July 2021
- GX Acquisition — SPAC Merger (April 2021)
SPAC merger · 51 slides · Apr 28, 2021
- GX Acquisition — SPAC Merger (February 2021)
SPAC merger · 55 slides · Feb 11, 2021
- SPAC Merger (January 2021)
SPAC merger · 54 slides · Jan 8, 2021